The role of estrogens in BRCA1/2 mutation carriers: reflections on the past, issues for the future.
Persons undergoing genetic testing for an inherited predisposition to cancer often raise questions about recommendations for follow-up care. Missing from current guidelines is consideration of the role of estrogens for BRCA1/BRCA2 mutation carriers. Potential implications of hormones for risk of cancer and effectiveness of risk-reduction strategies need to be considered in the design of comprehensive guidelines for high-risk women. Patients who are mutation carriers may ask questions about the use of oral contraceptives, hormone replacement, and utility of current screening modalities. Controversy exists, even when considering these issues for the general population, but become more imperative when considering young, unaffected women who carry an inherited genetic mutation making decisions that may have long-term health consequences. Many patients have considered estrogen ablation via prophylactic surgeries as risk-reduction interventions. This article reviews data regarding these issues, makes recommendations based on available information, and offers future perspectives for those identified at high risk for cancer because of genetic predisposition. Although questions remain regarding the potential implications of hormones for risk of cancer and effectiveness of risk-reduction strategies, all information should be considered when educating and caring for such patients.
de Carvalho
Maria
M
National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA. mdecarvalho@cc.nih.gov
Jenkins
Jean
J
Nehrebecky
Michele
M
Lahl
Lynda
L
D001943:Breast Neoplasms / Q000235:genetics / Q000517:prevention & control*; D003278:Contraceptives, Oral, Hormonal; D003657:Decision Making; D015914:Estrogen Replacement Therapy; D004967:Estrogens / Q000627:therapeutic use*; D005260:Female; D019398:Genes, BRCA1; D024522:Genes, BRCA2; D020022:Genetic Predisposition to Disease; D006801:Humans; D008408:Mastectomy; D010051:Ovarian Neoplasms / Q000235:genetics / Q000517:prevention & control*; D010052:Ovariectomy
D003278:Contraceptives, Oral, Hormonal; D004967:Estrogens